Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

E-ISSN： 1097-0142|120|13|1932-1938

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.13, 2014-07, pp. : 1932-1938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

Oncology, Vol. 78, Iss. 2, 2010-04 ,pp. : 141-149

Karger

Access to resources Recommend Favorite

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra Geyer Charles E

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele Vincenzi Bruno Tonini Giuseppe

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 554-558

Karger

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite